<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01470859</url>
  </required_header>
  <id_info>
    <org_study_id>KY2011-283</org_study_id>
    <nct_id>NCT01470859</nct_id>
  </id_info>
  <brief_title>The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease</brief_title>
  <official_title>a Pilot Follow-up Study of Investigating the Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Chinese Patients With Early Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Levodopa and non-ergot dopaminergic agonists such as pramipexole are both recommended as the
      first-line symptomatic treatment for early untreated Parkinson's disease (PD), previous
      clinical trial indicated that initial pramipexole owns advantage over levodopa regarding
      motor complications, on the contrary, less adverse effect like freezing and severe somnolence
      favors initial treatment of levodopa. Thus, it remains controversial that initiation of which
      medication will be better for those patients with early PD.

      Parkinson's disease-related spatial covariance patter (PDRP) is a new biomarker which can
      represent the network activity of brain and severity of PD. Based on the literatures and our
      previous data, the investigators hypothesize that PDRP will be served as a biomarker to help
      us evaluate and compare the effect of levodopa or pramipexole on the progression of PD, which
      might be able to provide further evidence for clinicians to address the above critical issue.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CALM-PD study found that Pramipexole can reduce the occurrence of motor complication compared
      with Levodopa used as initiative treatment, but it still remains debatable that initiation of
      which medication will be better for those patients with De Novo PD.

      PDRP (Parkinson's disease-related spatial covariance pattern) is a biomarker which can
      represent the network activity of cortico-striato-pallido-thalamocortical pathways and highly
      reproducible with stable network activity in individual subjects. The study published in &quot;J
      Neuroscience&quot; in 2010 showed that the abnormal PDRP antecede the appearance of motor signs by
      about 2 years, indicating PDRP might be a very promising biomarker for identifying PD at its
      early stage. Moreover, PDRP is able to represent the progression and severity of PD as well.
      It was reported that Levodopa can reduce the PD-related network activity, and the degree of
      network suppression correlates with the clinical improvement. However, there is no study
      currently showing the impact of pramipexole on brain PDRP network compared with levodopa as
      initiative treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Longitudinal Change of Brain Network Activity</measure>
    <time_frame>twice, baseline and 1 year after baseline</time_frame>
    <description>The brain network activity is evaluated by Parkinson's disease-related spatial covariance pattern(PDRP) value (Z score).
The change of brain network activity is calculated by the PDRP value (Z score) at V5 - the PDRP value (Z score) at V1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unified Parkinson's Disease Rating Score (UPDRS II, III)</measure>
    <time_frame>three times: baseline, 10 weeks, 1 year</time_frame>
    <description>baseline (1st visit, V1), completion of dosage titration within 10 weeks after baseline (2nd visit, V2), 1 year after baseline (final visit, V5) UPDRS II score 0-52 (13 items); UPDRS III score 0-56 (14 items); The more scores,the more severe; the two scales were evaluated separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Disease Questionnaire (PDQ39)</measure>
    <time_frame>twice baseline and 1 year</time_frame>
    <description>The PDQ39 score was assessed at baseline (1st visit, V1) and 1 year after baseline (final visit, V5).
PDQ39 score ranges from 0-156 (0-4 each item); the more score, the more severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hoehn&amp;Yahr (H&amp;Y) Staging</measure>
    <time_frame>twice baseline and 1 year</time_frame>
    <description>The Hoehn and Yahr scale is a commonly used scale for describing how the symptoms of Parkinson's disease progress and the disease stages. Bigger numbers indicate more symptoms and disease progression. H&amp;Y stage range from 0-5; the greater, the more severe.
The H&amp;Y stages of patients were evaluated at baseline (1st visit, V1), and 1 year after baseline (final visit, V5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Clinical Improvement as Evaluated by Global Impression Scale (CGI).</measure>
    <time_frame>twice, at 10 weeks(V2) and 1 year(V5)</time_frame>
    <description>Patients with a score &lt;= 2 (very much or much improved in relation to baseline) are considered as clinically improved.
The numbers of participants with clinical improvement are reported here. The completion of dosage titration within 10 weeks after baseline (visit 2) and 1 year after baseline (final visit)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Idiopathic Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>pramipexole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.375mg-4.5mg/day, flexible dosage according to an optimal improvement of movement dysfunction in PD patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levodopa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sinemet CR CRï¼Œ Controlled Release</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pramipexole</intervention_name>
    <description>tablets, 0.375mg-4.5mg/day divided by 3 times according to the optimal improvement of motor dysfunction in PD patients. duration is 1 year.</description>
    <arm_group_label>pramipexole</arm_group_label>
    <other_name>Sifrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sinemet CR</intervention_name>
    <description>tablet of Sinemet CR, dosage of levodopa ranging from 200mg-600mg/day divided by 2 or 3 times, Duration is 1 year</description>
    <arm_group_label>Levodopa</arm_group_label>
    <other_name>Sinemet CR 250' (Levodopa 200mg, and 50mg carbidopa)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  idiopathic Parkinson's disease meeting United Kingdom (UK) brain bank criteria

          -  De Novo

          -  Hoehn&amp;Yahr staging (H&amp;Y) I-II

        Exclusion Criteria:

          -  Atypical Parkinsonism

          -  Pregnant or breast-feeding women

          -  those with abnormal Liver/kidney function

          -  those participating other clinical trials within 30 days before being enrolled for
             this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Huashan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Izumi Y, Sawada H, Yamamoto N, Kume T, Katsuki H, Shimohama S, Akaike A. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. Eur J Pharmacol. 2007 Feb 28;557(2-3):132-40. Epub 2006 Nov 14.</citation>
    <PMID>17161393</PMID>
  </reference>
  <reference>
    <citation>Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005 Feb;62(2):241-8.</citation>
    <PMID>15710852</PMID>
  </reference>
  <reference>
    <citation>Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, Dhawan V, Eidelberg D. Changes in network activity with the progression of Parkinson's disease. Brain. 2007 Jul;130(Pt 7):1834-46. Epub 2007 Apr 30.</citation>
    <PMID>17470495</PMID>
  </reference>
  <reference>
    <citation>Ma Y, Tang C, Spetsieris PG, Dhawan V, Eidelberg D. Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J Cereb Blood Flow Metab. 2007 Mar;27(3):597-605. Epub 2006 Jun 28.</citation>
    <PMID>16804550</PMID>
  </reference>
  <reference>
    <citation>Tang CC, Poston KL, Dhawan V, Eidelberg D. Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci. 2010 Jan 20;30(3):1049-56. doi: 10.1523/JNEUROSCI.4188-09.2010.</citation>
    <PMID>20089913</PMID>
  </reference>
  <reference>
    <citation>Wang J, Ma Y, Huang Z, Sun B, Guan Y, Zuo C. Modulation of metabolic brain function by bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease. J Neurol. 2010 Jan;257(1):72-8. doi: 10.1007/s00415-009-5267-3. Epub 2009 Aug 7.</citation>
    <PMID>19662326</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2011</study_first_submitted>
  <study_first_submitted_qc>November 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2011</study_first_posted>
  <results_first_submitted>June 23, 2015</results_first_submitted>
  <results_first_submitted_qc>September 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 21, 2015</results_first_posted>
  <last_update_submitted>September 21, 2015</last_update_submitted>
  <last_update_submitted_qc>September 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Jian Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>De Novo parkinson's disease</keyword>
  <keyword>initial treatment</keyword>
  <keyword>pramipexole</keyword>
  <keyword>Levodopa</keyword>
  <keyword>Parkinson's disease-related spatial covariance pattern</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Pramipexole</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Levodopa</title>
          <description>Sinemet Controlled Release (CR)
Sinemet CR: tablet of Sinemet CR, dosage of levodopa ranging from 200mg-600mg/day divided by 2 or 3 times, Duration is 1 year</description>
        </group>
        <group group_id="P2">
          <title>Pramipexole</title>
          <description>0.375mg-4.5mg/day, flexible dosage according to an optimal improvement of movement dysfunction in PD patients
pramipexole: tablets, 0.375mg-4.5mg/day divided by 3 times according to the optimal improvement of motor dysfunction in PD patients. duration is 1 year.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pramipexole</title>
          <description>0.375mg-4.5mg/day, flexible dosage according to an optimal improvement of movement dysfunction in PD patients
pramipexole: tablets, 0.375mg-4.5mg/day divided by 3 times according to the optimal improvement of motor dysfunction in PD patients. duration is 1 year.</description>
        </group>
        <group group_id="B2">
          <title>Levodopa</title>
          <description>Sinemet CR
Sinemet CR: tablet of Sinemet CR, dosage of levodopa ranging from 200mg-600mg/day divided by 2 or 3 times, Duration is 1 year</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.87" spread="5.68"/>
                    <measurement group_id="B2" value="61.9" spread="6.66"/>
                    <measurement group_id="B3" value="62.9" spread="6.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Longitudinal Change of Brain Network Activity</title>
        <description>The brain network activity is evaluated by Parkinson's disease-related spatial covariance pattern(PDRP) value (Z score).
The change of brain network activity is calculated by the PDRP value (Z score) at V5 - the PDRP value (Z score) at V1.</description>
        <time_frame>twice, baseline and 1 year after baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa</title>
            <description>Sinemet CR
Sinemet CR: tablet of Sinemet CR, dosage of levodopa ranging from 200mg-600mg/day divided by 2 or 3 times, Duration is 1 year</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole</title>
            <description>0.375mg-4.5mg/day, flexible dosage according to an optimal improvement of movement dysfunction in PD patients
pramipexole: tablets, 0.375mg-4.5mg/day divided by 3 times according to the optimal improvement of motor dysfunction in PD patients. duration is 1 year.</description>
          </group>
        </group_list>
        <measure>
          <title>Longitudinal Change of Brain Network Activity</title>
          <description>The brain network activity is evaluated by Parkinson's disease-related spatial covariance pattern(PDRP) value (Z score).
The change of brain network activity is calculated by the PDRP value (Z score) at V5 - the PDRP value (Z score) at V1.</description>
          <units>Z-score in PDRP</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline (V5-V1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.70"/>
                    <measurement group_id="O2" value="0.61" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Z score at baseline (V1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread="1.54"/>
                    <measurement group_id="O2" value="3.61" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Z score at 1 year (V5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" spread="1.24"/>
                    <measurement group_id="O2" value="4.09" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.84</p_value>
            <p_value_desc>&quot;p&lt;0.05&quot; is indicating the threshold for statistical significance for this comparison</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>independent sample t-test The statistical analysis was performed on the changes of PDRP Z score between levodopa and pramipexole groups.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.93</p_value>
            <p_value_desc>&quot;p&lt;0.05&quot; is indicating the threshold for statistical significance for this comparison</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>independent sample t-test The statistical analysis was performed to compare the PDRP Z scores between levodopa and pramipexole groups at V1</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.31</p_value>
            <p_value_desc>&quot;p&lt;0.05&quot; is indicating the threshold for statistical significance for this comparison</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>independent sample t-test The statistical analysis was performed to compare the PDRP Z scores between levodopa and pramipexole groups at V5</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unified Parkinson's Disease Rating Score (UPDRS II, III)</title>
        <description>baseline (1st visit, V1), completion of dosage titration within 10 weeks after baseline (2nd visit, V2), 1 year after baseline (final visit, V5) UPDRS II score 0-52 (13 items); UPDRS III score 0-56 (14 items); The more scores,the more severe; the two scales were evaluated separately.</description>
        <time_frame>three times: baseline, 10 weeks, 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa</title>
            <description>Sinemet CR
Sinemet CR: tablet of Sinemet CR, dosage of levodopa ranging from 200mg-600mg/day divided by 2 or 3 times, Duration is 1 year</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole</title>
            <description>0.375mg-4.5mg/day, flexible dosage according to an optimal improvement of movement dysfunction in PD patients
pramipexole: tablets, 0.375mg-4.5mg/day divided by 3 times according to the optimal improvement of motor dysfunction in PD patients. duration is 1 year.</description>
          </group>
        </group_list>
        <measure>
          <title>Unified Parkinson's Disease Rating Score (UPDRS II, III)</title>
          <description>baseline (1st visit, V1), completion of dosage titration within 10 weeks after baseline (2nd visit, V2), 1 year after baseline (final visit, V5) UPDRS II score 0-52 (13 items); UPDRS III score 0-56 (14 items); The more scores,the more severe; the two scales were evaluated separately.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>UPDRS II at baseline (V1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="3.5"/>
                    <measurement group_id="O2" value="7.1" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UPDRS II (V2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="3.5"/>
                    <measurement group_id="O2" value="4.9" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UPDRS II at 1 year (V5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="3.5"/>
                    <measurement group_id="O2" value="8.4" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UPDRS III at baseline (V1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="7.7"/>
                    <measurement group_id="O2" value="23.1" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UPDRS III (V2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="4.2"/>
                    <measurement group_id="O2" value="20.1" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UPDRS III at 1 year (V5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="7.0"/>
                    <measurement group_id="O2" value="24.3" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.691</p_value>
            <p_value_desc>&quot;p&lt;0.05&quot; is indicating the threshold for statistical significance for this comparison</p_value_desc>
            <method>independent U test</method>
            <method_desc>independent U test The statistical analysis was performed to compare the UPDRS II scores at V1 scores between the levodopa and pramipexole groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.706</p_value>
            <p_value_desc>&quot;p&lt;0.05&quot; is indicating the threshold for statistical significance for this comparison</p_value_desc>
            <method>independent U test</method>
            <method_desc>independent U test The statistical analysis was performed to compare the UPDRS II scores at V2 scores between the levodopa and pramipexole groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.635</p_value>
            <p_value_desc>&quot;p&lt;0.05&quot; is indicating the threshold for statistical significance for this comparison</p_value_desc>
            <method>independent U test</method>
            <method_desc>independent U test The statistical analysis was performed to compare the UPDRS II scores at V5 scores between the levodopa and pramipexole groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.341</p_value>
            <p_value_desc>&quot;p&lt;0.05&quot; is indicating the threshold for statistical significance for this comparison</p_value_desc>
            <method>independent U test</method>
            <method_desc>independent U test The statistical analysis was performed to compare the UPDRS III scores at V1 scores between the levodopa and pramipexole groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.049</p_value>
            <p_value_desc>&quot;p&lt;0.05&quot; is indicating the threshold for statistical significance for this comparison</p_value_desc>
            <method>independent U test</method>
            <method_desc>independent U test The statistical analysis was performed to compare the UPDRS III scores at V2 scores between the levodopa and pramipexole groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.874</p_value>
            <p_value_desc>&quot;p&lt;0.05&quot; is indicating the threshold for statistical significance for this comparison</p_value_desc>
            <method>independent U test</method>
            <method_desc>independent U test The statistical analysis was performed to compare the UPDRS III scores at V5 scores between the levodopa and pramipexole groups</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parkinson's Disease Questionnaire (PDQ39)</title>
        <description>The PDQ39 score was assessed at baseline (1st visit, V1) and 1 year after baseline (final visit, V5).
PDQ39 score ranges from 0-156 (0-4 each item); the more score, the more severe.</description>
        <time_frame>twice baseline and 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa</title>
            <description>Sinemet CR
Sinemet CR: tablet of Sinemet CR, dosage of levodopa ranging from 200mg-600mg/day divided by 2 or 3 times, Duration is 1 year</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole</title>
            <description>0.375mg-4.5mg/day, flexible dosage according to an optimal improvement of movement dysfunction in PD patients
pramipexole: tablets, 0.375mg-4.5mg/day divided by 3 times according to the optimal improvement of motor dysfunction in PD patients. duration is 1 year.</description>
          </group>
        </group_list>
        <measure>
          <title>Parkinson's Disease Questionnaire (PDQ39)</title>
          <description>The PDQ39 score was assessed at baseline (1st visit, V1) and 1 year after baseline (final visit, V5).
PDQ39 score ranges from 0-156 (0-4 each item); the more score, the more severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PDQ39 at baseline (V1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.38" spread="10.94"/>
                    <measurement group_id="O2" value="20.36" spread="16.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PDQ39 at 1 year (V5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.36" spread="16.49"/>
                    <measurement group_id="O2" value="21.07" spread="12.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.720</p_value>
            <p_value_desc>&quot;p&lt;0.05&quot; is indicating the threshold for statistical significance for this comparison</p_value_desc>
            <method>independent U test</method>
            <method_desc>independent U test The statistical analysis was performed to compare the PDQ39 scores between levodopa and pramipexole group at V1</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.867</p_value>
            <p_value_desc>&quot;p&lt;0.05&quot; is indicating the threshold for statistical significance for this comparison</p_value_desc>
            <method>independent U test</method>
            <method_desc>independent U test The statistical analysis was performed to compare the PDQ39 scores between levodopa and pramipexole group at V5</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hoehn&amp;Yahr (H&amp;Y) Staging</title>
        <description>The Hoehn and Yahr scale is a commonly used scale for describing how the symptoms of Parkinson's disease progress and the disease stages. Bigger numbers indicate more symptoms and disease progression. H&amp;Y stage range from 0-5; the greater, the more severe.
The H&amp;Y stages of patients were evaluated at baseline (1st visit, V1), and 1 year after baseline (final visit, V5).</description>
        <time_frame>twice baseline and 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa</title>
            <description>Sinemet CR
Sinemet CR: tablet of Sinemet CR, dosage of levodopa ranging from 200mg-600mg/day divided by 2 or 3 times, Duration is 1 year</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole</title>
            <description>0.375mg-4.5mg/day, flexible dosage according to an optimal improvement of movement dysfunction in PD patients
pramipexole: tablets, 0.375mg-4.5mg/day divided by 3 times according to the optimal improvement of motor dysfunction in PD patients. duration is 1 year.</description>
          </group>
        </group_list>
        <measure>
          <title>Hoehn&amp;Yahr (H&amp;Y) Staging</title>
          <description>The Hoehn and Yahr scale is a commonly used scale for describing how the symptoms of Parkinson's disease progress and the disease stages. Bigger numbers indicate more symptoms and disease progression. H&amp;Y stage range from 0-5; the greater, the more severe.
The H&amp;Y stages of patients were evaluated at baseline (1st visit, V1), and 1 year after baseline (final visit, V5).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H&amp;Y at baselineï¼ˆV1ï¼‰</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="0.42"/>
                    <measurement group_id="O2" value="1.43" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H&amp;Y at 1 yearï¼ˆV5ï¼‰</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="0.47"/>
                    <measurement group_id="O2" value="1.82" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.793</p_value>
            <p_value_desc>&quot;p&lt;0.05&quot; is indicating the threshold for statistical significance for this comparison</p_value_desc>
            <method>indenpendent U test</method>
            <method_desc>independent U test The statistical analysis was performed to compare the H&amp;Y stages between levodopa and pramipexole group at V1</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.430</p_value>
            <p_value_desc>&quot;p&lt;0.05&quot; is indicating the threshold for statistical significance for this comparison</p_value_desc>
            <method>independent U test</method>
            <method_desc>independent U test The statistical analysis was performed to compare the H&amp;Y stages between levodopa and pramipexole groups at V5</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Clinical Improvement as Evaluated by Global Impression Scale (CGI).</title>
        <description>Patients with a score &lt;= 2 (very much or much improved in relation to baseline) are considered as clinically improved.
The numbers of participants with clinical improvement are reported here. The completion of dosage titration within 10 weeks after baseline (visit 2) and 1 year after baseline (final visit)</description>
        <time_frame>twice, at 10 weeks(V2) and 1 year(V5)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa</title>
            <description>Sinemet CR
Sinemet CR: tablet of Sinemet CR, dosage of levodopa ranging from 200mg-600mg/day divided by 2 or 3 times, Duration is 1 year</description>
          </group>
          <group group_id="O2">
            <title>Pramipexole</title>
            <description>0.375mg-4.5mg/day, flexible dosage according to an optimal improvement of movement dysfunction in PD patients
pramipexole: tablets, 0.375mg-4.5mg/day divided by 3 times according to the optimal improvement of motor dysfunction in PD patients. duration is 1 year.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Clinical Improvement as Evaluated by Global Impression Scale (CGI).</title>
          <description>Patients with a score &lt;= 2 (very much or much improved in relation to baseline) are considered as clinically improved.
The numbers of participants with clinical improvement are reported here. The completion of dosage titration within 10 weeks after baseline (visit 2) and 1 year after baseline (final visit)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with improvement at V2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with improvement at V5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.345</p_value>
            <p_value_desc>&quot;p&lt;0.05&quot; is indicating the threshold for statistical significance for this comparison</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>The statistical analysis was performed to compare the clinical improvement between levodopa and pramipexole groups at V2</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.410</p_value>
            <p_value_desc>&quot;p&lt;0.05&quot; is indicating the threshold for statistical significance for this comparison</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>The statistical analysis was performed to compare the clinical improvement between levodopa and pramipexole groups at V5</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Levodopa</title>
          <description>Sinemet CR
Sinemet CR: tablet of Sinemet CR, dosage of levodopa ranging from 200mg-600mg/day divided by 2 or 3 times, Duration is 1 year</description>
        </group>
        <group group_id="E2">
          <title>Pramipexole</title>
          <description>0.375mg-4.5mg/day, flexible dosage according to an optimal improvement of movement dysfunction in PD patients
pramipexole: tablets, 0.375mg-4.5mg/day divided by 3 times according to the optimal improvement of motor dysfunction in PD patients. duration is 1 year.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Courbature</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>In the further study, a larger sample size and strict enrollment of early PD patients may enhance the accuracy of clinical trial conclusions.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jian Wang</name_or_title>
      <organization>Department of Neurology, Huashan Hospital affiliated to Fudan University.</organization>
      <phone>+86-13321934789</phone>
      <email>wangjian336@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

